靶向白血病干细胞作为治疗的新策略

白血病干细胞被认为是白血病发生、发展及治疗后复发的根源,具有其特异的性状特征,以及自我更新、增殖和分化等能力.近年来以白血病干细胞作为治疗靶点已成为白血病治疗的一种新策略,目前的研究主要针对白血病干细胞表面分子、细胞内信号通路及与微环境的相互作用这三方面展开.对白血病干细胞的进一步认识将有助于提供新的更为有效的治疗靶点.     

Glyoxalase 1 as a Therapeutic Target in Cancer and Cancer Stem Cells

Methylglyoxal (MG) is a dicarbonyl compound formed in cells mainly by the spontaneous degradation of the triose phosphate intermediates of glycolysis. MG is a powerful precursor of advanced glycation end products, which lead to strong dicarbonyl and oxidative stress. Although divergent functions of MG have been observed depending on its concentration, MG is considered to be a potential anti-tumor factor due to its cytotoxic effects within the oncologic domain. MG detoxification is carried out by the glyoxalase system. Glyoxalase 1 (Glo1), the ubiquitous glutathione-dependent enzyme responsible for MG degradation, is considered to be a tumor promoting factor due to it catalyzing the removal of cytotoxic MG. Indeed, various cancer types exhibit increased expression and activity of Glo1 that closely correlate with tumor cell growth and metastasis. Furthermore, mounting evidence suggests that Glo1 contributes to cancer stem cell survival. In this review, we discuss the role of Glo1 in the malignant progression of cancer and its possible use as a promising therapeutic target for tumor therapy. We also summarize therapeutic outcomes of Glo1 inhibitors as prospective treatments for the prevention of cancer.     

胶质细胞的神经干细胞/祖细胞特性

近年来,关于胶质细胞有许多令人惊奇的发现。其中最令人感兴趣的是部分胶质细胞在体内外都表现出神经千细胞／祖细胞的特性,在适当条件下能分化成神经元、星形胶质细胞和／或少突胶质细胞。不仅存在于非哺乳类脊椎动物整个生命周期的放射胶质显示出这一特性,存在于成年哺乳动物脑室下区和颗粒下层的星形胶质细胞也是如此。在体外培养中,部分胶质细胞具有形成多潜能神经球的能力。在体内,胶质细胞充当前驱细胞时的命运受到细胞间相互作用、细胞因子、血脉系统、胞外基质以及基膜等所构建的微环境的影响。胶质细胞的这些特性将对神经修复产生深远影响。     

神经干细胞研究进展

神经干细胞(neural stem cells, NSCs)是中枢神经系统中保持分裂和分化潜能的细胞,对它的研究和应用已成为近年来脑科学研究的一个重要领域.神经干细胞体外培养技术的建立提供了对其进行研究的有力手段.目前的研究主要集中于神经干细胞在脑中的起源、分布及在中枢神经系统疾病治疗中的应用等方面.     

Iron Labeling and Pre-Clinical MRI Visualization of Therapeutic Human Neural Stem Cells in a Murine Glioma Model

Background

Treatment strategies for the highly invasive brain tumor, glioblastoma multiforme, require that cells which have invaded into the surrounding brain be specifically targeted. The inherent tumor-tropism of neural stem cells (NSCs) to primary and invasive tumor foci can be exploited to deliver therapeutics to invasive brain tumor cells in humans. Use of the strategy of converting prodrug to drug via therapeutic transgenes delivered by immortalized therapeutic NSC lines have shown efficacy in animal models. Thus therapeutic NSCs are being proposed for use in human brain tumor clinical trials. In the context of NSC-based therapies, MRI can be used both to non-invasively follow dynamic spatio-temporal patterns of the NSC tumor targeting allowing for the optimization of treatment strategies and to assess efficacy of the therapy. Iron-labeling of cells allows their presence to be visualized and tracked by MRI. Thus we aimed to iron-label therapeutic NSCs without affecting their cellular physiology using a method likely to gain United States Federal Drug Administration (FDA) approval.

Methodology

For human use, the characteristics of therapeutic Neural Stem Cells must be clearly defined with any pertubation to the cell including iron labeling requiring reanalysis of cellular physiology. Here, we studied the effect of iron-loading of the therapeutic NSCs, with ferumoxide-protamine sulfate complex (FE-Pro) on viability, proliferation, migratory properties and transgene expression, when compared to non-labeled cells. FE-Pro labeled NSCs were imaged by MRI at tumor sites, after intracranial administration into the hemisphere contralateral to the tumor, in an orthotopic human glioma xenograft mouse model.

Conclusion

FE-Pro labeled NSCs retain their proliferative status, tumor tropism, and maintain stem cell character, while allowing in vivo cellular MRI tracking at 7 Tesla, to monitor their real-time migration and distribution at brain tumor sites. Of significance, this work directly supports the use of FE-Pro-labeled NSCs for real-time tracking in the clinical trial under development: “A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically modified Neural Stem Cells Expressing Escherichia coli Cytosine Deaminase for Treatment of Recurrent High-Grade Gliomas”.     

神经干细胞迁移的研究进展

神经干细胞的定向迁移是胚胎神经系统发育的先决条件,同时在成体组织的许多生理、病理过程中也起着重要作用;研究发现,许多神经退行性疾病都与神经干细胞迁移的缺陷相关。近年来,越来越多的证据表明,无论是内源性的还是移植的神经干细胞都有向大脑损伤部位迁移的特性,显示出神经干细胞用于神经再生及损伤修复治疗的潜能。该文着重在神经干细胞的基本特性以及神经干细胞定向迁移的细胞与分子机制研究等方面进行了综述。     

Comparison of Spheroids Formed by Rat Glioma Stem Cells and Neural Stem Cells Reveals Differences in Glucose Metabolism and Promising Therapeutic Applications

Cancer stem cells (CSCs) are thought to be partially responsible for cancer resistance to current therapies and tumor recurrence. Dichloroacetate (DCA), a compound capable of shifting metabolism from glycolysis to glucose oxidation, via an inhibition of pyruvate dehydrogenase kinase was used. We show that DCA is able to shift the pyruvate metabolism in rat glioma CSCs but has no effect in rat neural stem cells. DCA forces CSCs into oxidative phosphorylation but does not trigger the production of reactive oxygen species and consecutive anti-cancer apoptosis. However, DCA, associated with etoposide or irradiation, induced a Bax-dependent apoptosis in CSCs in vitro and decreased their proliferation in vivo. The former phenomenon is related to DCA-induced Foxo3 and p53 expression, resulting in the overexpression of BH3-only proteins (Bad, Noxa, and Puma), which in turn facilitates Bax-dependent apoptosis. Our results demonstrate that a small drug available for clinical studies potentiates the induction of apoptosis in glioma CSCs.     

胎膜组织贴壁细胞：一种新的间质干细胞来源

[目的] 建立体外分离纯化胎膜组织贴壁细胞（fetal membrane derived adherent cells,FMDACs）的方法,并且研究FMDACs的基本生物学特性。[方法] 用胰酶消化法分离FMDACs,体外传代培养,并进行向成骨、成脂细胞的诱导分化培养,流式细胞仪、免疫细胞化学检测表面抗原,核型分析及致瘤性实验。[结果] 成功地进行了FMDACs的原代培养及传代培养,FMDACs具有良好的增殖能力,表达CD44、CD29,不表达CD34、CD14、CD45,经诱导后能够分化为成骨细胞和成脂细胞,传代多次后核型正常,无致瘤性。[结论] 胎膜组织中可以分离得到具有间质干细胞特性的贴壁细胞,具有较强的自我更新和多向分化能力,遗传背景稳定无致瘤性。FMDACs为临床应用进行细胞治疗和基因治疗提供了新的来源。     

Neural Stem Cells as Engraftable Packaging Lines Can Mediate Gene Delivery to Microglia: Evidence from Studying Retroviral env-Related Neurodegeneration

The induction of spongiform myeloencephalopathy by murine leukemia viruses is mediated primarily by infection of central nervous system (CNS) microglia. In this regard, we have previously shown that CasBrE-induced disease requires late, rather than early, virus replication events in microglial cells (W. P. Lynch et al., J. Virol. 70:8896-8907, 1996). Furthermore, neurodegeneration requires the presence of unique sequences within the viral env gene. Thus, the neurodegeneration-inducing events could result from microglial expression of retroviral envelope protein alone or from the interaction of envelope protein with other viral structural proteins in the virus assembly and maturation process. To distinguish between these possible mechanisms of disease induction, we engineered the engraftable neural stem cell line C17-2 into packaging/producer cells in order to deliver the neurovirulent CasBrE env gene to endogenous CNS cells. This strategy resulted in significant CasBrE env expression within CNS microglia without the appearance of replication competent virus. CasBrE envelope expression within microglia was accompanied by increased expression of activation markers F4/80 and Mac-1 (CD11b) but failed to induce spongiform neurodegenerative changes. These results suggest that envelope expression alone within microglia is not sufficient to induce neurodegeneration. Rather, microglia-mediated disease appears to require neurovirulent Env protein interaction with other viral proteins during assembly or maturation. More broadly, the results presented here prove the efficacy of a novel method by which neural stem cell biology may be harnessed for genetically manipulating the CNS, not only for studying neurodegeneration but also as a paradigm for the disseminated distribution of retroviral vector-transduced genes.     

脑胶质瘤神经干细胞治疗研究进展

脑胶质瘤是神经外科最常见的恶性肿瘤, 发病率约占全身肿瘤的5％,占儿童肿瘤的70％,且呈逐年上升的趋势。脑胶质瘤恶性程度高,生长迅速,５ 年生存率很低,其中高级别胶质瘤具有极强的侵袭能力,目前尚缺乏很有效的根治方法。手术切除肿瘤的难度很大,术后极易复发,预后比较差,对人类健康乃至生命的危害极大。随着分子生物学的发展以及相关生物技术的应用,从基因水平揭示脑胶质瘤的发生发展机制,并寻求有效的基因治疗方法成为人类研究肿瘤治疗新的研究方向。Reynolds 和Richards等先后从成年小鼠的纹状体中分离出能够不断增殖且具有多向分化潜能的细胞群,并提出了神经干细胞（neural stem cell, NSC）的概念。NSC具有高度增殖和自我更新的能力,且有迁移功能以及与正常脑组织良好融合的特性,这为基因治疗胶质瘤提供了良好的基础。     

脑胶质瘤神经干细胞治疗研究进展

脑胶质瘤是神经外科最常见的恶性肿瘤,发病率约占全身肿瘤的5%,占儿童肿瘤的70%,且呈逐年上升的趋势。脑胶质瘤恶性程度高,生长迅速,5年生存率很低,其中高级别胶质瘤具有极强的侵袭能力,目前尚缺乏很有效的根治方法。手术切除肿瘤的难度很大,术后极易复发,预后比较差,对人类健康乃至生命的危害极大。随着分子生物学的发展以及相关生物技术的应用,从基因水平揭示脑胶质瘤的发生发展机制,并寻求有效的基因治疗方法成为人类研究肿瘤治疗新的研究方向。Reynolds和Richards等先后从成年小鼠的纹状体中分离出能够不断增殖且具有多向分化潜能的细胞群,并提出了神经干细胞(neural stem cell,NSC)的概念。NSC具有高度增殖和自我更新的能力,且有迁移功能以及与正常脑组织良好融合的特性,这为基因治疗胶质瘤提供了良好的基础。     

神经干细胞迁移浅识

神经干细胞的迁移是近年来神经科学领域研究的热点之一.神经干细胞的增殖、迁移、分化和网络重建的特性为研究中枢神经系统退行性疾病及损伤后功能的恢复奠定了基础,其中神经干细胞的迁移发挥了重要作用.目前已经有大量研究探索神经干细胞的迁移,本文将分别从神经干细胞的迁移现象、神经干细胞迁移的影响因素及其应用意义等方面做一综述.     

Immune-Complex Mimics as a Molecular Platform for Adjuvant-Free Vaccine Delivery

Protein-based vaccine development faces the difficult challenge of finding robust yet non-toxic adjuvants suitable for humans. Here, using a molecular engineering approach, we have developed a molecular platform for generating self-adjuvanting immunogens that do not depend on exogenous adjuvants for induction of immune responses. These are based on the concept of Immune Complex Mimics (ICM), structures that are formed between an oligomeric antigen and a monoclonal antibody (mAb) to that antigen. In this way, the roles of antigens and antibodies within the structure of immune complexes are reversed, so that a single monoclonal antibody, rather than polyclonal sera or expensive mAb cocktails can be used. We tested this approach in the context of Mycobacterium tuberculosis (MTB) infection by linking the highly immunogenic and potentially protective Ag85B with the oligomeric Acr (alpha crystallin, HspX) antigen. When combined with an anti-Acr monoclonal antibody, the fusion protein formed ICM which bound to C1q component of the complement system and were readily taken up by antigen-presenting cells in vitro. ICM induced a strong Th1/Th2 mixed type antibody response, which was comparable to cholera toxin adjuvanted antigen, but only moderate levels of T cell proliferation and IFN-γ secretion. Unfortunately, the systemic administration of ICM did not confer statistically significant protection against intranasal MTB challenge, although a small BCG-boosting effect was observed. We conclude that ICM are capable of inducing strong humoral responses to incorporated antigens and may be a suitable vaccination approach for pathogens other than MTB, where antibody-based immunity may play a more protective role.     

BRCA-1 基因与神经干细胞

乳腺癌易感基因(Breast cancer susceptibility gene,Brca-1)是肿瘤抑制基因家族中的一员,它是乳腺癌特异性抑癌基因,1994年Miki等[1]采用定位克隆方法首次将Brca-1分离出来。Brca-1能防止细胞过快地或失去控制地生长和分化,在调节细胞进程、DNA损伤修复、细胞生长与凋亡及转录活化和抑制等多种生物学途径都发挥重要作用,Korhonen等2003年报道Brca-1基因可促进体外培养的大鼠来源的神经干细胞的增殖。     

Enriched Population of PNS Neurons Derived from Human Embryonic Stem Cells as a Platform for Studying Peripheral Neuropathies

Background

The absence of a suitable cellular model is a major obstacle for the study of peripheral neuropathies. Human embryonic stem cells hold the potential to be differentiated into peripheral neurons which makes them a suitable candidate for this purpose. However, so far the potential of hESC to differentiate into derivatives of the peripheral nervous system (PNS) was not investigated enough and in particular, the few trials conducted resulted in low yields of PNS neurons. Here we describe a novel hESC differentiation method to produce enriched populations of PNS mature neurons. By plating 8 weeks hESC derived neural progenitors (hESC-NPs) on laminin for two weeks in a defined medium, we demonstrate that over 70% of the resulting neurons express PNS markers and 30% of these cells are sensory neurons.

Methods/Findings

Our method shows that the hNPs express neuronal crest lineage markers in a temporal manner, and by plating 8 weeks hESC-NPs into laminin coated dishes these hNPs were promoted to differentiate and give rise to homogeneous PNS neuronal populations, expressing several PNS lineage-specific markers. Importantly, these cultures produced functional neurons with electrophysiological activities typical of mature neurons. Moreover, supporting this physiological capacity implantation of 8 weeks old hESC-NPs into the neural tube of chick embryos also produced human neurons expressing specific PNS markers in vivo in just a few days. Having the enriched PNS differentiation system in hand, we show for the first time in human PNS neurons the expression of IKAP/hELP1 protein, where a splicing mutation on the gene encoding this protein causes the peripheral neuropathy Familial Dysautonomia.

Conclusions/Significance

We conclude that this differentiation system to produce high numbers of human PNS neurons will be useful for studying PNS related neuropathies and for developing future drug screening applications for these diseases.     

LUZ-Y,a Novel Platform for the Mammalian Cell Production of Full-length IgG-bispecific Antibodies

The ability of bispecific antibodies to simultaneously bind two unique antigens has great clinical potential. However, most approaches utilized to generate bispecific antibodies yield antibody-like structures that diverge significantly from the structure of archetype human IgG, and those that do approach structural similarity to native antibodies are often challenging to engineer and manufacture. Here, we present a novel platform for the mammalian cell production of bispecific antibodies that differ from their parental mAbs by only a single point mutation per heavy chain. Central to this platform is the addition of a leucine zipper to the C terminus of the C_H3 domain of the antibody that is sufficient to drive the heterodimeric assembly of antibody heavy chains and can be readily removed post-purification. Using this approach, we developed various antibody constructs including one-armed Abs, bispecific antibodies that utilize a common light chain, and bispecific antibodies that pair light chains to their cognate heavy chains via peptide tethers. We have applied this technology to various antibody pairings and will demonstrate the engineering, purification, and biological activity of these antibodies herein.